ALGN:NSD-Align Technology Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 257.17

Change

+4.16 (+1.64)%

Market Cap

USD 19.21B

Volume

0.51M

Analyst Target

USD 325.93
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth. The segment also provides Invisalign moderate, lite and express packages, and Invisalign go and Invisalign Go Plus; retention products, Invisalign training, and adjusting tools used by dental professionals during the course of treatment; and Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and orthodontists software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface designed to enhance dental consultations; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan, as well as subscription software, disposables, rentals, leases, pay per scan, and CAD/CAM software solutions. The company was incorporated in 1997 and is headquartered in Tempe, Arizona. Address: 410 North Scottsdale Road, Tempe, AZ, United States, 85288

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

+7.92 (+1.64%)

USD 174.07B
COO The Cooper Companies, Inc. Com..

+0.57 (+0.52%)

USD 22.15B
HOLX Hologic Inc

+0.68 (+0.83%)

USD 18.85B
RGEN Repligen Corporation

+3.75 (+2.64%)

USD 7.84B
MMSI Merit Medical Systems Inc

+1.52 (+1.54%)

USD 5.60B
XRAY Dentsply Sirona Inc

+0.19 (+0.71%)

USD 5.33B
ICUI ICU Medical Inc

+5.05 (+2.87%)

USD 4.37B
AZTA Azenta Inc

+0.17 (+0.34%)

USD 2.41B
LMAT LeMaitre Vascular Inc

+1.33 (+1.50%)

USD 2.02B
STAA STAAR Surgical Company

+0.21 (+0.67%)

USD 1.59B

ETFs Containing ALGN

UGCE 3.86 % 0.00 %

N/A

N/A
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

+0.05 (+0.82%)

USD 2.77B
DBPG:F Xtrackers - S&P 500 2x Le.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.14% 52% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.14% 52% F 40% F
Trailing 12 Months  
Capital Gain -14.36% 42% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.36% 42% F 33% F
Trailing 5 Years  
Capital Gain 37.86% 69% C- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.86% 69% C- 65% D
Average Annual (5 Year Horizon)  
Capital Gain 22.62% 70% C- 79% B-
Dividend Return 22.62% 70% C- 79% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 73.21% 36% F 24% F
Risk Adjusted Return 30.90% 73% C 64% D
Market Capitalization 19.21B 95% A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.